Literature DB >> 16545534

Stability of warfarin solutions for drug-protein binding measurements: spectroscopic and chromatographic studies.

Annette C Moser1, Charles Kingsbury, David S Hage.   

Abstract

Warfarin is commonly used in drug-protein binding studies as a displacement marker for Sudlow site I on the protein human serum albumin (HSA). This study examined the stability of aqueous warfarin solutions prepared for such experiments. This was investigated using NMR spectroscopy and affinity chromatography. It was found by 1H NMR that warfarin underwent a slow first-order conversion in aqueous solution. The rate of this reaction increased with temperature, giving rate constants at pH 7.4 of 0.0086 h(-1) at 25 degrees C and 0.041 h(-1) at 37 degrees C. It was concluded from further 1H and 13C NMR studies, along with molecular modeling, that this process involved the conversion of the minor cyclic hemiketal form of warfarin to its major cyclic hemiketal. This reaction had a small but measurable effect on the binding of R- and S-warfarin to HSA, as demonstrated by HPLC using an immobilized HSA affinity column. From this work, general guidelines were developed concerning the usable lifetimes for warfarin that is prepared in aqueous solutions for studies of drug-protein binding.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16545534     DOI: 10.1016/j.jpba.2006.02.012

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  12 in total

1.  The effects of glycation on the binding of human serum albumin to warfarin and L-tryptophan.

Authors:  K S Joseph; David S Hage
Journal:  J Pharm Biomed Anal       Date:  2010-05-06       Impact factor: 3.935

2.  Characterization of the binding of sulfonylurea drugs to HSA by high-performance affinity chromatography.

Authors:  K S Joseph; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-06-01       Impact factor: 3.205

3.  Chromatographic analysis of the effects of fatty acids and glycation on binding by probes for Sudlow sites I and II to human serum albumin.

Authors:  Jeanethe Anguizola; Erin Debolt; D Suresh; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2015-10-09       Impact factor: 3.205

4.  Binding of tolbutamide to glycated human serum albumin.

Authors:  K S Joseph; Jeanethe Anguizola; David S Hage
Journal:  J Pharm Biomed Anal       Date:  2010-09-15       Impact factor: 3.935

5.  Evaluation of affinity microcolumns containing human serum albumin for rapid analysis of drug-protein binding.

Authors:  Michelle J Yoo; John E Schiel; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-04-24       Impact factor: 3.205

6.  Chromatographic analysis of acetohexamide binding to glycated human serum albumin.

Authors:  K S Joseph; Jeanethe Anguizola; Abby J Jackson; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-08-21       Impact factor: 3.205

7.  Evaluation of alternatives to warfarin as probes for Sudlow site I of human serum albumin: characterization by high-performance affinity chromatography.

Authors:  K S Joseph; Annette C Moser; Sara B G Basiaga; John E Schiel; David S Hage
Journal:  J Chromatogr A       Date:  2008-10-01       Impact factor: 4.759

8.  Evaluation of silica monoliths in affinity microcolumns for high-throughput analysis of drug-protein interactions.

Authors:  Michelle J Yoo; David S Hage
Journal:  J Sep Sci       Date:  2009-08       Impact factor: 3.645

9.  Studies of imipramine binding to human serum albumin by high-performance affinity chromatography.

Authors:  Michelle J Yoo; Quentin R Smith; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-03-10       Impact factor: 3.205

10.  Chromatographic studies of chlorpropamide interactions with normal and glycated human serum albumin based on affinity microcolumns.

Authors:  Pingyang Tao; Zhao Li; Ryan Matsuda; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2018-09-04       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.